Cytarabine 5'-Phosphate

Cytarabine 5'-Phosphate

SCHEMBL5094677

CC(=O)N[C@H]1[C@H]([C@H](O)[C@H](O)CO)O[C@](O)(C(N)=O)C[C@@H]1O.Nc1ccn([C@@H]2O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]2O)c(=O)n1

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
ST6GAL1 P15907 12/20 0.50
TSHR P16473 1/20 0.44
GLA P06280 1/20 0.44
P2RY2 P41231 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sialic Acid SCHEMBL30081458 0.95 ST6GAL1 (0.50) ST6GAL1TSHRGLAP2RY2
Sialic Acid SCHEMBL2296552 0.95 ST6GAL1 (0.50) ST6GAL1TSHRGLAP2RY2
Sialic Acid SCHEMBL30081457 0.95 ST6GAL1 (0.50) ST6GAL1TSHRGLAP2RY2
Sialic Acid SCHEMBL21068057 0.95 ST6GAL1 (0.50) ST6GAL1TSHRGLAP2RY2
Sialic Acid SCHEMBL29668373 0.95 ST6GAL1 (0.50) ST6GAL1TSHRGLAP2RY2
SCHEMBL237564 0.90 ST6GAL1 (0.45) ST6GAL1TSHRGLA
Sialic Acid SCHEMBL28452247 0.89 ST6GAL1 (0.54) ST6GAL1TSHRGLA
Cytarabine 5'-Phosphate SCHEMBL26630601 0.89 ST6GAL1 (0.47) ST6GAL1TSHRGLAP2RY2
Cytarabine 5'-Phosphate SCHEMBL19423351 0.89 ST6GAL1 (0.47) ST6GAL1TSHRGLAP2RY2
Cytarabine 5'-Phosphate SCHEMBL15652697 0.88 ST6GAL1 (0.47) ST6GAL1TSHRGLAP2RY2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080319183-A1 Branched Polymeric Sugars and Nucleotides Thereof NEOSE TECHNOLOGIES, INC. (US) 2008-12-25 US claimed
EP-1720892-A4 BRANCHED POLYMERIC SUGARS AND NUCLEOTIDES THEREOF NEOSE TECHNOLOGIES INC (US) 2007-07-25 EP claimed
EP-1720892-A2 BRANCHED POLYMERIC SUGARS AND NUCLEOTIDES THEREOF Neose Technologies, Inc. (US) 2006-11-15 EP claimed
WO-2005072371-A2 BRANCHED POLYMERIC SUGARS AND NUCLEOTIDES THEREOF NEOSE TECHNOLOGIES, INC. (US) 2005-08-11 WO claimed
EP-1720892-B1 Branched polymer-modified sugars and nucleotides BIOGENERIX AG (DE) 2013-07-24 EP disclosed
US-20080319183-A1 Branched Polymeric Sugars and Nucleotides Thereof NEOSE TECHNOLOGIES, INC. (US) 2008-12-25 US disclosed
EP-1720892-A4 BRANCHED POLYMERIC SUGARS AND NUCLEOTIDES THEREOF NEOSE TECHNOLOGIES INC (US) 2007-07-25 EP disclosed
EP-1720892-A2 BRANCHED POLYMERIC SUGARS AND NUCLEOTIDES THEREOF Neose Technologies, Inc. (US) 2006-11-15 EP disclosed
WO-2005072371-A2 BRANCHED POLYMERIC SUGARS AND NUCLEOTIDES THEREOF NEOSE TECHNOLOGIES, INC. (US) 2005-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080319183-A1 Branched Polymeric Sugars and Nucleotides Thereof GALE, NUDT14, GNE ST6GAL1 93/4885TSHR 4614/4885GLA 515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.